Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18932827 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME | October 2024 | May 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 18660698 | ANTICANCER COMPOSITIONS | May 2024 | April 2025 | Allow | 11 | 2 | 0 | No | No |
| 18636148 | METHODS AND COMPOSITIONS FOR REDUCING SYMPTOMS OF PARKINSON'S DISEASE | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18444104 | ORAL FORMULATIONS OF FASUDIL WITH ION EXCHANGE RESIN | February 2024 | June 2024 | Allow | 4 | 1 | 0 | No | No |
| 18411576 | PSILOCIN MUCATE | January 2024 | August 2024 | Allow | 7 | 1 | 1 | No | No |
| 18402989 | ETHYL 3-[4,4-BIS(4-CHLOROPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]PROPANOATE AS AN ANTIMICROBIAL COMPOUND | January 2024 | March 2024 | Allow | 3 | 0 | 0 | No | No |
| 18385648 | 8-(3-BROMOBENZYLIDENEAMINO)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18494554 | Dosing Regimens for Elagolix | October 2023 | May 2025 | Allow | 19 | 1 | 0 | No | No |
| 18482456 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | October 2023 | February 2025 | Abandon | 16 | 3 | 0 | No | No |
| 18481539 | RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF | October 2023 | April 2025 | Allow | 18 | 1 | 0 | No | No |
| 18474990 | Colonic Microbiota Responsive Polymer And Its Preparation Method And Use | September 2023 | September 2024 | Allow | 11 | 0 | 0 | No | No |
| 18467705 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | September 2023 | May 2024 | Abandon | 8 | 1 | 0 | No | No |
| 18462054 | Methods of Administering Elagolix | September 2023 | March 2024 | Allow | 6 | 1 | 0 | No | No |
| 18234232 | METHODS AND COMPOSITIONS FOR REDUCING SYMPTOMS OF PARKINSON'S DISEASE | August 2023 | February 2024 | Allow | 6 | 1 | 0 | No | No |
| 18347393 | ESKETAMINE FOR THE TREATMENT OF DEPRESSION | July 2023 | December 2024 | Abandon | 18 | 3 | 0 | No | No |
| 18340067 | STABLE PHARMACEUTICAL COMPOSITIONS OF EDARAVONE | June 2023 | February 2025 | Allow | 20 | 4 | 1 | No | No |
| 18336476 | MULTIPHASIC CONTRACEPTIVE REGIMEN FOR ORAL COMBINATION DRUG FORMULATION OF PROGESTIN AND ESTROGEN | June 2023 | April 2025 | Allow | 22 | 1 | 0 | No | No |
| 18205634 | METHODS FOR TREATING GI TRACT DISORDERS | June 2023 | June 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18200152 | PROGESTOGEN-ONLY ORAL CONTRACEPTION | May 2023 | June 2025 | Allow | 25 | 1 | 0 | No | No |
| 18318210 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | May 2023 | March 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18316553 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | May 2023 | March 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18315706 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | May 2023 | March 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18310755 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | May 2023 | March 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18307048 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX | April 2023 | February 2024 | Allow | 10 | 1 | 0 | No | No |
| 18296851 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | April 2023 | March 2024 | Abandon | 11 | 1 | 0 | No | No |
| 18129177 | METHODS FOR INCREASING SEPIAPTERIN PLASMA EXPOSURE | March 2023 | February 2025 | Allow | 23 | 1 | 0 | No | No |
| 18194257 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | March 2023 | March 2024 | Abandon | 11 | 2 | 0 | No | No |
| 18192244 | ANTICANCER COMPOSITIONS | March 2023 | March 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18177585 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | March 2023 | August 2023 | Allow | 6 | 1 | 0 | No | No |
| 18171790 | METHODS OF TREATING TESTOSTERONE DEFICIENCY | February 2023 | May 2024 | Abandon | 15 | 2 | 0 | Yes | No |
| 18171077 | ORAL FORMULATIONS OF FASUDIL WITH ION EXCHANGE RESIN | February 2023 | December 2023 | Allow | 10 | 1 | 1 | No | No |
| 18092688 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | January 2023 | July 2023 | Allow | 6 | 1 | 0 | No | No |
| 18091510 | COMPOSITIONS THAT PREFERENTIALLY POTENTIATE SUBTYPES OF GABAA RECEPTORS AND METHODS OF USE THEREOF | December 2022 | April 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18077279 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | December 2022 | May 2025 | Abandon | 30 | 1 | 0 | No | No |
| 18062764 | Method of Adjuvant Cancer Treatment | December 2022 | May 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18059554 | SPIRO-OXAZOLONES | November 2022 | July 2024 | Allow | 19 | 0 | 0 | No | No |
| 18059924 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | November 2022 | January 2024 | Allow | 14 | 1 | 0 | No | No |
| 18053478 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | November 2022 | October 2023 | Allow | 11 | 0 | 0 | No | No |
| 18053248 | COMPOSITIONS FOR IMPROVING SEXUAL FUNCTION | November 2022 | February 2025 | Abandon | 27 | 1 | 0 | No | No |
| 17963712 | COMPOUNDS AND THEIR USES FOR ALLEVIATING MENOPAUSE-ASSOCIATED SYMPTOMS | October 2022 | March 2023 | Allow | 5 | 1 | 0 | No | No |
| 17937934 | Oral Allopregnanolone Compositions and Methods of Use | October 2022 | November 2024 | Allow | 26 | 4 | 1 | No | No |
| 17952238 | Dry Powder Foamable Formulations for Delivery of Medicaments through the Mucosa | September 2022 | June 2023 | Allow | 8 | 1 | 1 | Yes | No |
| 17934889 | BORTEZOMIB COMPOSITIONS | September 2022 | April 2023 | Allow | 6 | 1 | 0 | No | No |
| 17950785 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | September 2022 | August 2024 | Allow | 23 | 0 | 1 | No | No |
| 17945865 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | September 2022 | March 2025 | Abandon | 30 | 3 | 1 | No | No |
| 17901078 | DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS | September 2022 | June 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17823559 | TARGETING PAPAIN-LIKE PROTEASE FOR BROAD-SPECTRUM CORONAVIRUSES INHIBITION | August 2022 | January 2024 | Allow | 16 | 2 | 0 | No | No |
| 17823080 | Oral Allopregnanolone Compositions and Methods of Use | August 2022 | March 2024 | Allow | 18 | 2 | 1 | No | No |
| 17893999 | COMPOUNDS AND THEIR USES FOR ALLEVIATING MENOPAUSE-ASSOCIATED SYMPTOMS | August 2022 | May 2025 | Allow | 33 | 1 | 0 | No | No |
| 17821342 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | August 2022 | February 2023 | Allow | 6 | 2 | 0 | No | No |
| 17819858 | CHIRAL DIARYL MACROCYCLES AND USES THEREOF | August 2022 | January 2025 | Allow | 29 | 2 | 0 | No | No |
| 17814591 | FORMULATIONS OF TESTOSTERONE AND METHODS OF TREATMENT THEREWITH | July 2022 | March 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17813619 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VASOMOTOR SYMPTOMS | July 2022 | October 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17809192 | AQUEOUS ORAL PHARMACEUTICAL SUSPENSION COMPOSITIONS | June 2022 | September 2024 | Allow | 27 | 1 | 0 | No | No |
| 17846806 | TANNIN FORMULATIONS FOR AGRICULTURAL USE IN PLANTS | June 2022 | December 2024 | Abandon | 30 | 4 | 0 | Yes | No |
| 17846322 | VISCOUS BUDESONIDE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT | June 2022 | April 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17845459 | TANNIN FORMULATIONS FOR AGRICULTURAL USE IN PLANTS | June 2022 | June 2024 | Allow | 23 | 4 | 0 | Yes | No |
| 17845105 | DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE | June 2022 | March 2024 | Allow | 21 | 1 | 0 | No | No |
| 17843506 | MEDROXYPROGESTERONE ACETATE INJECTABLE COMPOSITIONS AND METHODS OF USE | June 2022 | October 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17840203 | CYPROTERONE ACETATE COMPOSITIONS AND USES THEREOF | June 2022 | April 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17806526 | INJECTABLE FORMULATIONS | June 2022 | March 2025 | Allow | 33 | 2 | 0 | No | No |
| 17836120 | PROSTACYCLIN ANALOGUE FORMULATIONS | June 2022 | December 2024 | Abandon | 30 | 2 | 0 | No | No |
| 17824288 | PHOSPHOLIPID FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | May 2022 | June 2025 | Allow | 36 | 1 | 1 | No | No |
| 17778953 | CURCUMIN COMPOSITIONS FOR OSTEOARTHRITIS AND JOINT WELLNESS | May 2022 | June 2025 | Allow | 37 | 0 | 1 | No | No |
| 17745662 | COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL INFLAMMATION | May 2022 | March 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17742665 | ANTI-METHANOGENIC COMPOSITIONS AND USES THEREOF | May 2022 | June 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17740698 | DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS | May 2022 | May 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17740673 | Compositions and Methods for Treating CNS Disorders | May 2022 | August 2022 | Allow | 3 | 1 | 0 | No | No |
| 17736494 | METHOD FOR TREATMENT OF PARKINSON'S DISEASE | May 2022 | August 2022 | Allow | 3 | 1 | 0 | No | No |
| 17720777 | METHOD FOR TREATMENT OF PARKINSON'S DISEASE | April 2022 | December 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17715133 | DUAL ACTIVE INSECTICIDAL COMPOSITIONS | April 2022 | August 2023 | Allow | 17 | 1 | 0 | No | No |
| 17715911 | 1-METHYLXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | April 2022 | April 2025 | Allow | 36 | 2 | 1 | No | No |
| 17655483 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | March 2022 | December 2023 | Allow | 21 | 1 | 0 | No | No |
| 17698361 | METHODS OF TREATING COVID-19 | March 2022 | April 2025 | Abandon | 37 | 1 | 1 | No | No |
| 17653950 | Use of Isoxazoline Derivatives for the Treatment or Prevention of Arthropod Infestations in Poultry | March 2022 | June 2024 | Allow | 28 | 1 | 1 | No | No |
| 17689576 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | March 2022 | September 2023 | Allow | 18 | 1 | 0 | No | No |
| 17684579 | METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | March 2022 | November 2024 | Allow | 32 | 1 | 1 | No | No |
| 17683624 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX | March 2022 | April 2023 | Allow | 13 | 3 | 0 | Yes | No |
| 17639206 | INDUSTRIAL PROCESS FOR THE PREPARATION OF HIGH PURITY ESTETROL | February 2022 | February 2023 | Allow | 12 | 0 | 0 | No | No |
| 17637859 | TREATMENT OF MENSTRUAL CYCLE-INDUCED SYMPTOMS | February 2022 | November 2022 | Allow | 8 | 1 | 0 | No | No |
| 17651877 | AQUEOUS ORAL PHARMACEUTICAL SUSPENSION COMPOSITIONS | February 2022 | May 2022 | Allow | 3 | 0 | 0 | No | No |
| 17590784 | Method of treating late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency by individually tailored glucocorticoid regimen | February 2022 | February 2024 | Allow | 24 | 0 | 0 | No | No |
| 17586942 | Methods of Administering Elagolix | January 2022 | June 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17580954 | Pharmaceutical Compositions Comprising a Hydroxyethylquercetin Glucuronide | January 2022 | June 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17581818 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | January 2022 | May 2024 | Allow | 27 | 1 | 0 | No | No |
| 17581030 | TANNIN FORMULATIONS FOR AGRICULTURAL USE IN PLANTS | January 2022 | May 2022 | Allow | 3 | 1 | 0 | No | No |
| 17579263 | METHODS AND COMPOSITIONS FOR TREATING CANCER | January 2022 | February 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17567473 | METHOD FOR TREATMENT OF PARKINSON'S DISEASE | January 2022 | April 2022 | Allow | 3 | 1 | 0 | No | No |
| 17644491 | COMBINATION OF PI3K INHIBITOR AND C-MET INHIBITOR | December 2021 | January 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17550253 | LEVOTHYROXINE LIQUID FORMULATIONS | December 2021 | December 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17547720 | PROGESTERONE RECEPTOR ANTAGONIST DOSAGE FORM | December 2021 | December 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17542855 | TOPICAL CORTICOSTEROIDS FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT | December 2021 | July 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17533984 | METHOD FOR TREATMENT OF PARKINSON'S DISEASE | November 2021 | July 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17526493 | COMPOSITIONS COMPRISING OXYGENATED CHOLESTEROL SULFATE AND AT LEAST ONE OF POLYALKYLENE GLYCOL, CARBOXYMETHYL CELLULOSE AND POLYOXYLGLYCERIDE | November 2021 | June 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17610236 | PHARMACEUTICAL COMPOSITION CONTAINING BREXANOLONE, GANAXOLONE, OR ZURANOLONE, AND USE THEREOF | November 2021 | April 2025 | Allow | 41 | 1 | 1 | No | No |
| 17515945 | PROPHYLACTIC AND THERAPEUTIC DRUG FOR NONALCOHOLIC FATTY LIVER DISEASE | November 2021 | March 2024 | Allow | 28 | 1 | 1 | No | No |
| 17607867 | New Kaurane analogues, their preparation and therapeutically uses | October 2021 | April 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17513946 | THERAPEUTIC AGENT FOR FIBROSIS | October 2021 | February 2023 | Allow | 16 | 0 | 0 | No | No |
| 17513199 | METHODS FOR TREATING VITILIGO LESIONS HAVING IMPROVED EFFICACY | October 2021 | December 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17508951 | TRANSDERMAL TREATMENT FOR ERECTILE DYSFUNCTION | October 2021 | June 2024 | Allow | 32 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUI, SAN MING R.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HUI, SAN MING R works in Art Unit 1627 and has examined 445 patent applications in our dataset. With an allowance rate of 65.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 25 months.
Examiner HUI, SAN MING R's allowance rate of 65.4% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HUI, SAN MING R receive 1.72 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by HUI, SAN MING R is 25 months. This places the examiner in the 64% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +21.5% benefit to allowance rate for applications examined by HUI, SAN MING R. This interview benefit is in the 70% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 30.5% of applications are subsequently allowed. This success rate is in the 52% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 48.0% of cases where such amendments are filed. This entry rate is in the 67% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 81.8% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 88.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 26.1% are granted (fully or in part). This grant rate is in the 17% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.6% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.